Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.41 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.37 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.37 |
| ▸ | TSPO | P30536 | 1/20 | 0.37 |
| ▸ | APEX1 | P27695 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.36 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1888097 | 0.90 | PPARG (0.38) | PPARGHCRTR2AGTR1AGTR2TSPO | |
| SCHEMBL1885452 | 0.85 | TRPM8 (0.41) | PPARGHCRTR2PTGDR2SMN1; SMN2 | |
| SCHEMBL1889207 | 0.84 | SMN1; SMN2 (0.42) | PPARGHCRTR2TSPOPTGDR2TAS2R14 | |
| SCHEMBL1889687 | 0.78 | PTGDR2 (0.39) | PPARGAPEX1PTGDR2 | |
| SCHEMBL1889690 | 0.78 | PPARG (0.42) | PPARGAGTR1AGTR2APEX1PTGDR2 | |
| SCHEMBL3051896 | 0.75 | SMN1; SMN2 (0.40) | PPARGHCRTR2GAASMN1; SMN2NPSR1 | |
| SCHEMBL3047903 | 0.75 | TRPM8 (0.38) | PPARGHCRTR2SMN1; SMN2 | |
| SCHEMBL1887685 | 0.75 | KMT2A (0.43) | PTGDR2TAS2R14GAASMN1; SMN2 | |
| SCHEMBL1886642 | 0.74 | AGTR1 (0.46) | PPARGAGTR1AGTR2APEX1PTGDR2 | |
| SCHEMBL1888333 | 0.73 | PTGDR2 (0.49) | PTGDR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7732618-B2 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2010-06-08 | — | — | US | claimed |
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH | 2011-05-05 | — | — | US | disclosed |
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH | 2011-05-05 | — | — | US | disclosed |
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH | 2011-05-05 | — | — | US | disclosed |
| US-7732618-B2 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732618-B2 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2010-06-08 | — | — | US | disclosed |
| US-7732618-B2 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1814865-A4 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH CORP (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1814865-A2 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | Athersys, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH | 2006-05-18 | — | — | US | disclosed |
| WO-2006034418-A2 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | ATHERSYS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | HRH2, TBXA2R, PTGDR2 | PPARG 123/4885HCRTR2 126/4885AGTR1 124/4885 |
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | HRH2, TBXA2R, PTGDR2 | PPARG 123/4885HCRTR2 126/4885AGTR1 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.